Anika Therapeutics Correlations
ANIK Stock | USD 17.20 0.23 1.36% |
The current 90-days correlation between Anika Therapeutics and Eliem Therapeutics is 0.07 (i.e., Significant diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anika Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anika Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Anika Therapeutics Correlation With Market
Modest diversification
The correlation between Anika Therapeutics and DJI is 0.29 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Anika Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Anika |
Moving together with Anika Stock
0.76 | ME | 23Andme Holding | PairCorr |
0.65 | VALN | Valneva SE ADR | PairCorr |
0.82 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.84 | PFE | Pfizer Inc Aggressive Push | PairCorr |
0.71 | IPSC | Century Therapeutics | PairCorr |
0.73 | MTEM | Molecular Templates | PairCorr |
0.73 | NKTX | Nkarta Inc | PairCorr |
0.73 | TPST | Tempest Therapeutics | PairCorr |
0.78 | AGL | agilon health Buyout Trend | PairCorr |
0.78 | TCHH | Trustcash Holdings | PairCorr |
0.73 | SHG | Shinhan Financial | PairCorr |
0.71 | EC | Ecopetrol SA ADR | PairCorr |
0.65 | WF | Woori Financial Group | PairCorr |
0.86 | HYMTF | Hyundai Motor | PairCorr |
0.84 | TLK | Telkom Indonesia Tbk | PairCorr |
Moving against Anika Stock
0.9 | MDGL | Madrigal Pharmaceuticals | PairCorr |
0.54 | RNXT | RenovoRx | PairCorr |
0.37 | KEP | Korea Electric Power | PairCorr |
0.79 | BAC | Bank of America Aggressive Push | PairCorr |
0.76 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
0.75 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
0.63 | T | ATT Inc Sell-off Trend | PairCorr |
0.62 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
0.62 | INTC | Intel Fiscal Year End 23rd of January 2025 | PairCorr |
0.46 | HPQ | HP Inc | PairCorr |
0.37 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
Related Correlations Analysis
-0.01 | 0.87 | -0.52 | 0.83 | -0.66 | ELYM | ||
-0.01 | -0.17 | 0.1 | 0.11 | 0.01 | HCWB | ||
0.87 | -0.17 | -0.52 | 0.72 | -0.57 | SCPH | ||
-0.52 | 0.1 | -0.52 | -0.42 | 0.49 | MIST | ||
0.83 | 0.11 | 0.72 | -0.42 | -0.6 | MCRB | ||
-0.66 | 0.01 | -0.57 | 0.49 | -0.6 | LUMO | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Anika Stock performing well and Anika Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Anika Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
ELYM | 3.92 | (0.95) | 0.00 | (5.36) | 0.00 | 6.21 | 34.87 | |||
HCWB | 13.22 | 4.45 | 0.42 | (1.48) | 7.39 | 22.00 | 352.85 | |||
SCPH | 2.68 | (0.82) | 0.00 | (0.32) | 0.00 | 4.30 | 20.70 | |||
MIST | 1.92 | 0.21 | 0.13 | 0.25 | 1.60 | 7.19 | 18.66 | |||
MCRB | 4.68 | 0.01 | (0.02) | 0.25 | 5.68 | 10.00 | 28.84 | |||
LUMO | 2.77 | 0.61 | 0.15 | (3.14) | 2.60 | 6.35 | 26.13 |
Anika Therapeutics Corporate Management
Ian McLeod | VP Officer | Profile | |
James Chase | Senior Marketing | Profile | |
Bart Bracy | VP Americas | Profile | |
Lisa Funiciello | Vice Resources | Profile | |
Mark Namaroff | Executive Communications | Profile | |
Michael CPA | Executive Officer | Profile | |
Charles III | VP Counsel | Profile |